Arrowhead Pharmaceuticals, Inc. (ARWR) News
Filter ARWR News Items
ARWR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARWR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ARWR News From Around the Web
Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trialThe investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for patients living with obesity. |
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityPASADENA, Calif., December 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a k |
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PASADENA, Calif., December 19, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved "inducement" grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and |
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated DiseasesPASADENA, Calif., December 11, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. |
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past weekArrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the last... |
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatmentARO-ALK7 is engineered to suppress the activin A receptor type 1C gene in fat cells. |
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of ObesityPASADENA, Calif., December 03, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead’s leadership in the delivery of siRNA to multip |
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced a global license and collaboration agreement with Sarepta Therapeutics (SRPT) in which Arrowhead is set to receive $825 million, consisting of $500 million in cash and |
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 ConferencesPASADENA, Calif., December 02, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: |
Arrowhead price target lowered to $24 from $27 at BernsteinBernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s fiscal Q4 update centered primarily on the large collaboration deal announced with Sarepta (SRPT) (SPRT) and implications for its own strategy going forward, the analyst tells investors in a research note. The firm takes a “very positive view” on the deal, both for its transformational impact on Arrowhead’s cash position and the greater focus it will bring |